E
BPMC

Ergoteles’s Blueprint Medicines BPMC Stock Holding History

Ergoteles’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,955
Closed -$1.79M – 1287
2022
Q4 		$1.79M Buy
+40,955
New +$1.96M 0.07% 303
2022
Q2 		– Sell
-32,958
Closed -$2.1M – 1652
2022
Q1 		$2.1M Buy
+32,958
New +$2.37M 0.08% 249

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ergoteles's BPMC Position: Q1 2023 in Review

Ergoteles sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 40,955 shares — an estimated $1.79M sold.

Ergoteles first reported a position in BPMC in Q1 2022 and held it in 2 quarters. The position peaked at $2.1M in Q1 2022. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • Ergoteles reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 40,955 Blueprint Medicines shares in Q1 2023, an estimated $1.79M.
  • Ergoteles first reported a position in Blueprint Medicines in Q1 2022 and held it in 2 quarters.
  • Ergoteles's Blueprint Medicines position peaked at $2.1M in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.